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994Introduction: Cross-sex hormone therapy is an essential part of gender affirming treatment of transgender in-
dividuals. Studies systematically describing the physical and psychological effects of hormonal treatment of
transgender persons are scarce.
Aim: The aim of the current protocol is to evaluate clinical and side-effects of cross-sex hormonal treatment in
trans persons.
Methods: The European Network for the Investigation of Gender Incongruence (ENIGI) is a multicenter
prospective study. Because of the relatively low prevalence of the condition and small number of specialized
centers, international collaboration is warranted. Four European treatment centers, Ghent, Oslo, Florence, and
Amsterdam, developed a common study and treatment protocol.
Main Outcome Measures: Outcome measures include hormonal and metabolic parameters, bone density,
secondary sex and anthropometric characteristics, and physical and psychological well-being.
Results: Thus far, 333 trans women and 343 trans men have been included in the ENIGI Endocrine protocol.
The study is still ongoing.
Conclusion: In recent years, the number of trans persons seeking gender affirming treatment has increased.
However, well-designed prospective studies evaluating safety and effectiveness of current hormonal treatment
protocols are lacking. Therefore we started the ENIGI collaboration. In this article we give a detailed description
of the study protocol, objectives, and design of the ENIGI Endocrine protocol.
J Sex Med 2016;13:994e999. Copyright  2016, International Society for Sexual Medicine. Published by Elsevier
Inc. All rights reserved.
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.org/10.1016/j.jsxm.2016.03.371assigned gender that has been present for at least 6 months.1 This
condition has a great negative impact on physical, social, and
psychological well-being and a large proportion of trans persons
(but not all) desire gender affirming treatment.
For most trans individuals, hormonal treatment is an essential
part of their sex change. Harry Benjamin (January 12,
1885eAugust 24, 1986) born in Germany, was an American
endocrinologist and sexologist who was one of the pioneers
treating patients with cross-sex hormones around the middle of
the twentieth century. Although gender reassignment was still a
matter of much debate, over half a century later hormone therapy
and surgical reassignment are accepted as the mainstay treatment
for gender dysphoria.2
Currently, endocrine treatment regimens are not standardized
and include various forms, applications, and dosages of estrogens,
progestins and (anti) androgens.3 Thus far, no randomized inter-
vention trials have been performed to determine the best treatment
regimens. Furthermore, no large prospective studies have evaluatedJ Sex Med 2016;13:994e999
ENIGI: Endocrine Part 995(side) effects of cross-sex hormone treatment (CHT) in a struc-
tured manner. The European Network for the Investigation of
Gender Incongruence (ENIGI) collaboration creates a unique
opportunity to perform the much-needed research in this field.
The main objective of the study is to describe the clinical effects
and side-effects of hormonal treatment in adults with GD. All
participating centers will evaluate these clinical effects using the
same standardized measurements and questionnaires.
Previously, Kreukels et al4 presented the diagnostic protocol
and psychological assessments used in the ENIGI Mental Health
protocol. The close collaboration between both mental health
and endocrine specialists offers a unique possibility for trans-
lational and interdisciplinary research. Furthermore, the inter-
national and multicenter approach of this study facilitates
collaboration and exchange between different European expert
centers. Another major advantage of this collaboration is that we
can include larger number of patients in our study. This is of
specific importance, because although patient numbers are
increasing, GD is still a relatively rare condition.AIMS
The aims of the endocrine part of the ENIGI collaboration is
to evaluate the effects of CHT on hormonal and metabolic pa-
rameters, bone density, secondary sex and anthropometric
characteristics, and physical and psychological well-being of trans
persons. In this article, we present the study design and data
collection procedures of the ENIGI Endocrine protocol.SUBJECTS AND METHODS
Participating Centers
The ENIGI study is a multicenter prospective cohort study.
So far, 4 West European gender identity clinics are participating
in this collaboration. They include Ghent University Hospital,
Belgium; VU University Medical Center in Amsterdam, the
Netherlands; Rikshospitalet in Oslo, Norway; and University
Hospital in Florence, Italy. These centers all use the ENIGI
Mental Health protocol. The first trans persons were included in
the ENIGI Endocrine protocol in 2010. Data presented in this
article represent an update of our inclusions until March 12,
2015. At that time the first conference of the European Profes-
sional Association for Transgender Health (EPATH) was orga-
nized in Ghent, Belgium. Inclusion of trans persons is still
ongoing in all participating centers.
The overall study protocol was approved by the Ethical
Committee of Ghent University Hospital, Belgium. Every
participating clinical center also obtained approval of their local
ethical committees.Study Participants
All patients underwent a standardized diagnostic procedure to
confirm the diagnosis GD/gender incongruence and assessJ Sex Med 2016;13:994e999eligibility for treatment. The procedure of the ENIGI Mental
Health protocol is described in Kreukels et al.4 In short, the
mean duration of the diagnostic phase varies between 6 and 12
months and consists of regular meetings with a psychologist and/
or a psychiatrist. Once the diagnosis has been confirmed and
there are no physical, psychological or social contraindications,
hormonal treatment is started. In all centers, psychological
counselling is offered during this phase, which is also called the
“Social Transition Phase.” During this 12- to 18-month period,
persons experience life in the desired gender role on a daily basis.
Once persons successfully go through this phase and there are no
somatic contraindications, they are referred to the surgeon if they
desire gender affirming surgery. All included subjects are above
16 years (Ghent and Oslo), above 17 years (Amsterdam), or
above 18 years (Florence).
People are included in the ENIGI Endocrine protocol when
they start medical treatment for GD/gender incongruence. Data
on fulfillment of diagnostic criteria of current manuals for clas-
sification is collected in the ENIGI Mental Health protocol.
Patients are eligible to participate if they have not used cross-sex
hormones before and if they have sufficient knowledge of the
native languages: Dutch or French for participants from Ghent,
and Dutch, Italian, and Norwegian for patients from Amster-
dam, Florence, and Oslo, respectively. At the start of CHT,
patients receive oral and written information of the ENIGI
endocrine protocol by their physician and written informed
consent is obtained according to the institutional guidelines.Treatment Protocol
Trans women
Cyproterone acetate in a once daily dose of 50 mg is started in
combination with an estradiol agent. In Ghent, Amsterdam, and
Florence, estradiol valerate is prescribed 2 mg twice daily,
whereas in Oslo 4 mg is given in 1 single dose. Although not well
established, the ENIGI medical team felt that risk of thrombosis
from estrogens was greater with oral agents than with trans-
dermal preparations, perhaps due to the “first pass effect” of the
liver. Therefore the protocol calls for transdermal estrogens for
patients older than 45 years of age. In Amsterdam and Ghent we
prescribe estradiol patches in a dose of 100 mcg/24 hours. For
some medical conditions, such as a history of thrombosis,
treatment is started at a lower dose. In Florence patients can also
choose from estradiol emidrate gel 1 mg twice daily.
Trans men
As not all testosterone treatment regimens are reimbursed in
the different European countries, treatment protocols differ be-
tween the clinical centers. In Ghent and Oslo, testosterone
undecanoate 1000 mg once per 12 weeks (Nebido) is prescribed.
In the Netherlands, currently testosterone undecanoate in-
jections are not covered by health insurance companies, so most
patients choose between testosterone gel in a daily dose of 50 mg
or testosterone esters 250 mg injections (Sustanon) every 2
996 Dekker et alweeks. If they prefer, testosterone undecanoate injections are
prescribed.
In Florence, costs for hormonal treatment are covered by The
National Health Service only in some regions. Trans men can
choose between testosterone gel in a daily dose of 50 mg or
different injectable formulations: testosterone undecanoate 1000
mg once per 12 weeks or testosterone enanthate 250 mg (Testo-
enant) injections every 2 weeks.Data Collection
Demographic characteristics
At baseline (during the diagnostic phase) demographic char-
acteristics are assessed. They include age, age of onset of GD,
quality of life, education level (low: lower education and lower
vocational; middle: secondary education, secondary vocational
and high school; high: higher vocational, bachelor, master and
PhD), living situation, employment (no employment, full-time,
part-time, and education), and sexual orientation.Clinical Measurements
At baseline and during each visit, body weight and height are
measured in light indoor clothing without shoes. Additionally
waist, hip, and chest circumference are measured. The chest
circumference is measured at the level of the nipples and just
below the breasts, so cup size can be inferred. Blood pressure is
measured using an electronic blood pressure monitor. Grip
strength at the dominant hand is measured using an adjustable
hand-held standard grip device (JAMAR hand dynamometer,
Sammons and Preston; Bolingbrook, IL, USA).5,6
The Ferriman-Gallwey score is used to evaluate and quantify
body hair in trans men. Because of shaving and local manipu-
lation the Ferriman-Gallwey score is not meaningful in trans
women.7 Acne is assessed using the Global Acne Grading Scale
(GAGS).8 At baseline a detailed medical history is taken to
evaluate contraindications for hormonal treatment. At each visit
current smoking status, alcohol use, medication use, and inter-
current diseases are assessed.
At all visits all clinical measures are filled out on a standardized
form. After the visit this information is entered in our database
manually. Measures that are used for clinical purpose are also
documented in our medical records and include length, weight,
blood pressure, current smoking status and alcohol use, inter-
current disease, and medication use.
Serum determinations
Venous blood samples are obtained between 8 AM and 10
AM after overnight fasting. Samples are analyzed at the local
laboratory, as they are also used for clinical purposes. Serum
measurements include haematocrit, alkaline phosphatase,
gamma-glutamyltransferase, aspartate-aminotransferase, alanine-
aminotransferase, creatinine, glucose, total cholesterol, tri-
glycerides, high-density lipoprotein cholesterol, low-densitylipoprotein cholesterol, 25-hydroxycholecalciferol, calcium, al-
bumin, testosterone, estradiol, sex hormone-binding globulin,
luteinizing hormone, prolactin, and prostate-specific antigen (in
trans women aged 45 years and older).Serum Bank
Next to the serum samples drawn for clinical evaluation
additional samples are stored for future research purposes. These
samples are collected at baseline, after 3 months and 1, 2 and 10
years of CHT. Next to this, at baseline, buffy coats are stored for
future DNA research. In the near future we will start by
extracting DNA from these samples. All samples are stored
at 80C at every local center.Bone Measurements and Body Composition
Body fat and lean mass, bone mineral content, bone area, and
areal bone mineral density at the lumbar spine and left proximal
femur (total hip and femoral neck region) are measured using
dual X-ray absorptiometry (DEXA). In Ghent additional bone
measurements are available using peripheral quantitative
computed tomography (pQCT).9 Bone measurements are per-
formed at baseline, and after 1, 2, and 10 years of hormonal
treatment.Questionnaires
At each visit questionnaires are handed out by our secretary
staff or physicians. It takes approximately 15 to 20 minutes to fill
out these forms. The questionnaires are processed using Tele-
Form automated data extraction (Hewlett-Packard Company;
Palo Alto, CA, USA).
Physical activity: Habitual physical activity is measured using
the Baecke Activity Questionnaire, which consists of 16 ques-
tions classified into 3 different dimensions: work, sport, and non-
sports leisure activity. Each domain can receive a score from 1 to
5 points, thus allowing a total score from 3 (minimum activity)
to 15 (maximum activity).10
Experienced vocal performance: The Trans Voice Questionnaire
is a 30-item self-administered questionnaire that evaluates the
psychosocial consequences of voice disorders and consists of 3
dimensions: functional, physical, and emotional impairment. A
score of 0 is equivalent to no disability and a score of 120 is
equivalent to maximum disability.11
Side-effects questionnaire: We constructed a questionnaire to
evaluate side-effects of hormonal treatment such as psychovege-
tative symptoms, physical complaints, cognition, emotionality
and sexuality, genital complaints, and pain.
The following 4 questionnaires are part of the Mental Health-
Endocrinology protocol:
Positive Affect Negative Affect Scale (PANAS): The PANAS is a
20-item questionnaire that measures long-term changes in affect.
Participants are asked to what extent they experience certainJ Sex Med 2016;13:994e999
Table 1. Characteristics of the study population and cross-sex
hormonel treatment regimens
Trans
women
Trans
men
Total number of trans persons (n) 333 343
Number of trans persons
per center (n)
VU University Medical
Centre Amsterdam
178 185
Ghent University Hospital 130 69
Rikshospitalet University
Hospital Oslo
13 81
University Hospital Florence 12 8
Cross-sex hormonal treatment
at start of study (n)
Estradiol valerate
4 mg/day + CPA
221
Estradiol patches 100 mcg/
24 hours + CPA
109
Estradiol gel* + CPA 3
Testosterone im 1000 mg
once per 12 weeks
177
Testosterone im 250 mg
once per 2 weeks
90
Testosterone gel 50 mg/day 76
Age, median (range) (y) 30 (16e65) 24 (16e51)
Systolic blood pressure
(mm Hg)
127 (3.3) 122 (6.2)
Diastolic blood pressure
(mm Hg)
79 (3.1) 75 (4.5)
Body weight (kg) 77 (2.8) 71 (2.5)
Length (m) 1.77 (0.02) 1.67 (0.02)
BMI (kg/m2) 24.4 (0.8) 25.3 (0.7)
Current smoking (%) 32.7 32.1
Alcohol, median (25th/75th
percentile) (units/wk)
0 (0e2) 0 (0e2)
CPA ¼ cyproterone acetate; im ¼ intramuscular.
Data are presented as means (SD) unless stated otherwise.
*Patients treated with estradiol emidrate gel 1 mg twice daily.
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from “very little” to “very much”.12
Aggression proneness: The STAXI-2 State Anger scale is a 15-
item questionnaire that evaluates aggression. Participants rank
certain statements along a 4-point continuum from “not at all” to
“very much.” The questionnaire evaluates angry feelings on 3
subscales: feeling angry, feeling like expressing anger verbally,
and feeling like expressing anger physically.13
Sexual desire: The Sexual Desire Inventory (SDI) is a self-
administered 14-item questionnaire that aims to measure sex-
ual desire. The SDI measures the individual’s thoughts as well as
actual experiences. Fourteen questions assess the strength, fre-
quency, and importance of an individual’s desire for sexual ac-
tivity with others and by themselves. The score ranges from 0 (no
sexual desire) to 112 (maximum desire).14
Sexual orientation questionnaire: This short questionnaire
consists of 4 questions in the “background data interview” which
is part of the ENIGI Mental Health protocol. These questions
evaluate gender roles in sexual fantasy, and sexual orientation.
Psychological questionnaires: For a detailed description of the
additional psychological questionnaires used in the ENIGI
Mental Health protocol, see Kreukels et al.4 These question-
naires are administered at baseline (during the diagnostic phase)
and evaluate gender identity and dysphoria, body image, quality
of life, psychological functioning, and psychiatric comorbidity.
Follow-up and data management
The short-term follow-up consists of ENIGI visits at baseline
and after 3, 6, 9, 12, and 24 months of CHT. We also will
perform mid-term follow-up after 10 years of hormonal treat-
ment. In the future we will introduce long-term follow-up visits
as well.
Currently, data management is performed by dedicated PhD
students and laboratory technicians. We exchange databases at
our twice-yearly research meetings. In the near future, data ex-
change and storage will be coordinated by a central ENIGI data
manager. All ENIGI participants are given an ENIGI research
number by which their data are anonymized.
New research proposals are discussed at our ENIGI meetings
and all senior research partners have to agree with the proposal.
Upon agreement the researcher gets access to the data needed for
that specific research question. New ENIGI partners are
welcome to join our initiative by contacting one of the senior
investigators and filling out a questionnaire that evaluates quality
of delivered health care and number of trans persons treated.RESULTS
The baseline characteristics of our study population are pre-
sented in Table 1. So far 333 trans women and 343 trans men
have been included in the ENIGI Endocrine protocol. The mean
age at start of follow-up was 30 years and 24 years for transJ Sex Med 2016;13:994e999women and trans men, respectively. Most trans women are
treated with estradiol valerate tablets (n ¼ 221), whereas fewer
patients are treated with transdermal oestradiol patches (n ¼
109) or estradiol gel (n ¼ 3). The most frequently prescribed
hormonal treatment for trans men is testosterone undecanoate
injections (n ¼ 177). Ninety trans men are treated with testos-
terone injections every 2 weeks (Sustanon or Testo-enant) and
76 trans men with testosterone gel. We have complete data on
age and treatment at start of follow-up. Missing data is below 7
percent for all other characteristics presented in Table 1.DISCUSSION
The ENIGI Endocrine protocol studies the effects and side-
effects of CHT in transgender individuals. Data collection
began in 2010 and at time of the first EPATH conference in
998 Dekker et alMarch 2015 in Ghent (Belgium), 333 trans women and 343
trans men were included from 4 different European expertise
centers.
Recently, the first results of the ENIGI collaboration were
published. Wierckx et al evaluated side-effects and safety of CHT
in 53 trans men and 53 trans women. For this study patients
from Ghent University Hospital and Rikshospitalet University
Hospital Oslo were included. The authors concluded that the
treatment modalities used were effective and carried a low risk for
side-effects and adverse events at short-time follow-up.15
Furthermore, Van Caenegem et al showed that although trans
women had a lower bone mineral density and cortical bone size
before the start of CHT, their skeletal status was well preserved
during the first 2 years of their hormonal treatment, despite
substantial muscle loss.16 For this study 49 trans women were
included from Ghent University Hospital. Additional analyses
using the (combined) data of the different centers are ongoing.
To our knowledge, the ENIGI initiative is the first large
prospective cohort study to evaluate clinical and side-effects of
CHT. In line with the findings of Wierckx et al, previous
observational studies showed that CHT of trans men yields a
low risk of adverse events in the short and longer term.17,18
However, observational studies with longer follow-up times
show that the incidence of cardiovascular disease in trans
women is higher compared with the control population,
whereas this increase is not observed in trans men on testos-
terone treatment.17 Limitations of these studies include the
retrospective design (all studies), relative low number of study
subjects,19-21 and relatively short median duration of follow-up
of most of these studies (between 4.4 and 9.0 years).19-23 This
is of importance, because the largest increase in incidence of
lethal cardiovascular events in trans women seems to occur after
10 years of CHT. This was shown by a study by Asscheman
et al on total and cause-specific mortality of trans persons
receiving hormonal treatment in which 966 trans women and
365 trans men were included with a median duration of follow-
up of 18.5 years.24 However, in this study most lethal ischemic
cardiac events observed were related to ethinyl estradiol use.
This synthetic estrogen is not part of current CHT protocols
since the observation of the increased risk of venous thrombosis
related to this compound.22 Well-designed prospective studies
in large samples are needed to evaluate safety and effectiveness
of current hormonal treatment of trans persons.
In ENIGI, all centers use the same study protocol. We use the
same standardized questionnaires and use the same devices to
measure clinical outcomes. In this way we will be able to include
patients from participating centers in combined studies and
compare results of the different centers easily. However, the
hormonal treatment protocols differ somewhat between partici-
pating centers. The most important reason for these discrep-
ancies is that not all treatment modalities are reimbursed in the
different European countries. For instance, testosterone unde-
canoate injections are not covered in the Netherlands. Althoughthese differences were not introduced intentionally, they may
provide us with insights into possible different clinical and side-
effects of different treatment options for trans persons. Although
we are not performing a randomized controlled trial, important
clinical lessons will be learnt.
Up till now we have not collected data on total number of
eligible patients, and number and reasons of non-participation.
However, in our experience the majority of patients were very
motivated to participate in the study and wanted to contribute
to improve transgender health care. At our latest research
meeting we agreed to start collecting these data from June 2016
onward. Another important improvement is that in the near
future data storage and exchange will be coordinated by a
central ENIGI data manager. However, due to lack of funding
we have not been able to launch a central ENIGI website yet
which can be used for data management, exchange of research
protocols, and application of new ENIGI partners. Hopefully,
with enough resources we will be able to launch this website in
the future.
A better understanding and knowledge of clinical and side-
effects of CHT will be essential to optimize hormonal treat-
ment of trans persons. Once a substantial database has been
collected, variations in products and dosages may be introduced
in the hormonal treatment protocol of trans persons.Corresponding Author: M.J.H.J. Dekker, MD, PhD, VU
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